Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Alosetron. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A known ✓ | P46098 | 2/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.54 |
| ▸ | HTR2B | P41595 | 5/20 | 0.54 |
| ▸ | ADRA2C | P18825 | 4/20 | 0.54 |
| ▸ | HTR2A | P28223 | 4/20 | 0.54 |
| ▸ | HTR2C | P28335 | 4/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | CASP6 | P55212 | 1/20 | 0.53 |
| ▸ | HRH1 | P35367 | 9/20 | 0.43 |
| ▸ | DRD3 | P35462 | 6/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.43 |
| ▸ | DRD2 | P14416 | 5/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.43 |
| ▸ | DRD1 | P21728 | 4/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.43 |
| ▸ | DRD5 | P21918 | 3/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alosetron SCHEMBL148316 | 0.84 | HTR2A (0.74) | KCNH2HTR2BADRA2CHTR2AHTR2C | |
| Alosetron SCHEMBL7371660 | 0.83 | CASP6 (0.74) | KCNH2HTR2BADRA2CHTR2AHTR2C | |
| Alosetron SCHEMBL311317 | 0.83 | CASP6 (0.74) | KCNH2HTR2BADRA2CHTR2AHTR2C | |
| Alosetron SCHEMBL2229995 | 0.79 | KCNH2 (0.65) | KCNH2HTR2BADRA2CHTR2AHTR2C | |
| SCHEMBL20027463 | 0.73 | KCNH2 (0.57) | KCNH2HTR2BADRA2CHTR2AHTR2C | |
| SCHEMBL20022665 | 0.73 | HTR2A (0.56) | KCNH2HTR2BADRA2CHTR2AHTR2C | |
| Alosetron SCHEMBL631 | 0.71 | KCNH2 (1.00) | KCNH2HTR2BADRA2CHTR2AHTR2C | |
| Alosetron SCHEMBL29377019 | 0.71 | KCNH2 (1.00) | KCNH2HTR2BADRA2CHTR2AHTR2C | |
| Alosetron SCHEMBL806 | 0.70 | CASP6 (1.00) | KCNH2HTR2BADRA2CHTR2AHTR2C | |
| Alosetron SCHEMBL29387635 | 0.70 | CASP6 (1.00) | KCNH2HTR2BADRA2CHTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10543223-B2 | Mannose derivatives useful for treating pathologies associated with adherent E. coli | ENTEROME (FR) | 2020-01-28 | — | — | US | disclosed |
| EP-3331893-B1 | MANNOSE DERIVATIVES USEFUL FOR TREATING PATHOLOGIES ASSOCIATED WITH ADHERENT E. COLI | ENTEROME (FR) | 2019-05-22 | — | — | EP | disclosed |
| US-20180235991-A1 | MANNOSE DERIVATIVES USEFUL FOR TREATING PATHOLOGIES ASSOCIATED WITH ADHERENT E. COLI | NANTES UNIVERSITE (FR) | 2018-08-23 | — | — | US | disclosed |
| EP-3331893-A1 | MANNOSE DERIVATIVES USEFUL FOR TREATING PATHOLOGIES ASSOCIATED WITH ADHERENT E. COLI | Enterome (FR) | 2018-06-13 | — | — | EP | disclosed |
| WO-2017021549-A1 | MANNOSE DERIVATIVES USEFUL FOR TREATING PATHOLOGIES ASSOCIATED WITH ADHERENT E. COLI | ENTEROME (FR) | 2017-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180235991-A1 | MANNOSE DERIVATIVES USEFUL FOR TREATING PATHOLOGIES ASSOCIATED WITH ADHERENT E. COLI | FPR3, CCR3, RXFP3 | HTR3A 490/4885KCNH2 3342/4885HTR2B 3113/4885 |
| US-10543223-B2 | Mannose derivatives useful for treating pathologies associated with adherent E. coli | FPR3, CCR3, RXFP3 | HTR3A 490/4885KCNH2 3342/4885HTR2B 3113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.